Advertisement

Journal of Gastrointestinal Surgery

, Volume 23, Issue 1, pp 76–83 | Cite as

Platelet-Albumin Score as a Sensitive Measure for Surgical Risk Prediction and Survival Outcomes of Patients with Hepatocellular Carcinoma

  • Junichi Shindoh
  • Yusuke Kawamura
  • Yuta Kobayashi
  • Yoshitaka Kiya
  • Toshitaka Sugawara
  • Norio Akuta
  • Masahiro Kobayashi
  • Yoshiyuki Suzuki
  • Kenji Ikeda
  • Masaji Hashimoto
2018 SSAT Plenary Presentation
  • 72 Downloads

Abstract

Background

Given that patients with hepatocellular carcinoma (HCC) usually suffer from dual diseases (i.e., HCC and underlying liver disease), a complete survival estimation model is difficult to establish because both the oncological stage and the underlying liver function affect the survival outcome.

Methods

A new surgical risk model for estimating the survival of patients undergoing resection for HCC was created using a cohort treated between 1995 and 2013 (training set, n = 889), and its efficacy was then validated using a cohort treated between 2014 and 2017 (validation set, n = 310).

Results

The following statistical model was developed based on the results of multivariate analysis: albumin-platelet (PAL) score = − 0.777 × albumin (g/dL) − 0.575 × log10 (platelet count [104/μL]) (cut-off value, − 3.77 and − 3.04 for grading). A time-dependent receiver-operating curve analysis revealed that the area under the curve for 3-year survival was 0.644 in the training set and 0.666 in the validation set. The incidences of postoperative morbidity were 14.0% for PAL grade 1, 18.7% for PAL grade 2, and 26.1% for PAL grade 3 (P = 0.039), while the incidences of refractory ascites were 2.2, 7.1, and 12.5% (P = 0.005), respectively, in the training set. The reproducibility of these results was confirmed in the validation set with morbidity rates of 13.5, 23.3, and 40.7% (P = 0.003), respectively, and the incidences of refractory ascites were 0.7, 10.7, and 22.2% (P < 0.0001), respectively.

Conclusions

The PAL score can be used as a grading system for the stratification of survival outcomes and surgical risks of patients undergoing HCC resection.

Keywords

Hepatocellular carcinoma Liver function Albumin Platelet Survival 

Notes

Source of Funding

This study is supported by the institutional research grant for clinical study at Toranomon Hospital.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379(9822):1245–55.CrossRefGoogle Scholar
  2. 2.
    Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, O'Beirne J, Fox R, Skowronska A, Palmer D, Yeo W, Mo F, Lai P, Inarrairaegui M, Chan SL, Sangro B, Miksad R, Tada T, Kumada T, Toyoda H. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 2015;33(6):550–8.CrossRefGoogle Scholar
  3. 3.
    Shindoh J, Makuuchi M, Matsuyama Y, Mise Y, Arita J, Sakamoto Y, Hasegawa K, Kokudo N. Complete removal of the tumor-bearing portal territory decreases local tumor recurrence and improves disease-specific survival of patients with hepatocellular carcinoma. J Hepatol 2016;64(3):594–600.CrossRefGoogle Scholar
  4. 4.
    Na SK, Yim SY, Suh SJ, Jung YK, Kim JH, Seo YS, Yim HJ, Yeon JE, Byun KS, Um SH. ALBI versus Child-Pugh grading systems for liver function in patients with hepatocellular carcinoma. J Surg Oncol. 2018;117(5):912–21.CrossRefGoogle Scholar
  5. 5.
    Hiraoka A, Kumada T, Kudo M, Hirooka M, Tsuji K, Itobayashi E, Kariyama K, Ishikawa T, Tajiri K, Ochi H, Tada T, Toyoda H, Nouso K, Joko K, Kawasaki H, Hiasa Y, Michitaka K, Real-Life Practice Experts for HCCSG, Group HCC. Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications. Liver Cancer 2017;6(3):204–15.CrossRefGoogle Scholar
  6. 6.
    Huitzil-Melendez FD, Capanu M, O'Reilly EM, Duffy A, Gansukh B, Saltz LL, Abou-Alfa GK. Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol 2010;28(17):2889–95.CrossRefGoogle Scholar
  7. 7.
    Amin M, Edge S, Greene F, Byrd D, Washington M, Gershnwald J, Compton C, Hess K, Sullivan D, Jessup J, Brierley J, Gaspar L, Schilsky R, Balch C, Winchester D, Asare E, Madera M, Gress D, Meyer L. AJCC Cancer Staging Manual. Philadelphia: Springer International Publishing, 2017.Google Scholar
  8. 8.
    Makuuchi M, Kosuge T, Takayama T, Yamazaki S, Kakazu T, Miyagawa S, Kawasaki S. Surgery for small liver cancers. Semin Surg Oncol 1993;9(4):298–304.CrossRefGoogle Scholar
  9. 9.
    Yokoyama Y, Nishio H, Ebata T, Igami T, Sugawara G, Nagino M. Value of indocyanine green clearance of the future liver remnant in predicting outcome after resection for biliary cancer. Br J Surg 2010;97(8):1260–8.CrossRefGoogle Scholar
  10. 10.
    Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibanes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009;250(2):187–96.CrossRefGoogle Scholar
  11. 11.
    Koch M, Garden OJ, Padbury R, Rahbari NN, Adam R, Capussotti L, Fan ST, Yokoyama Y, Crawford M, Makuuchi M, Christophi C, Banting S, Brooke-Smith M, Usatoff V, Nagino M, Maddern G, Hugh TJ, Vauthey JN, Greig P, Rees M, Nimura Y, Figueras J, DeMatteo RP, Buchler MW, Weitz J. Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. Surgery 2011;149(5):680–8.CrossRefGoogle Scholar
  12. 12.
    Mullen JT, Ribero D, Reddy SK, Donadon M, Zorzi D, Gautam S, Abdalla EK, Curley SA, Capussotti L, Clary BM, Vauthey JN. Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg 2007;204(5):854–62; discussion 62-4.CrossRefGoogle Scholar
  13. 13.
    Ishizawa T, Hasegawa K, Kokudo N, Sano K, Imamura H, Beck Y, Sugawara Y, Makuuchi M. Risk factors and management of ascites after liver resection to treat hepatocellular carcinoma. Arch Surg 2009;144(1):46–51.CrossRefGoogle Scholar
  14. 14.
    Japan LCSGo. The general rules for the clinical and pathological study of primary liver cancer, 4th ed. Tokyo: Kanehara; 2000.Google Scholar
  15. 15.
    Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56(4):918–28.CrossRefGoogle Scholar
  16. 16.
    Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19(3):329–38.CrossRefGoogle Scholar
  17. 17.
    The Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998;28(3):751–5.Google Scholar
  18. 18.
    Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003;38(3):207–15.CrossRefGoogle Scholar
  19. 19.
    Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 2014;146(7):1691–700 e3.CrossRefGoogle Scholar
  20. 20.
    Child C, Turcotte J. Surgery and portal hypertension. In: Child C, editor. The liver and portalhypertension. Philadelphia: Saunders; 1964. p. 50–64.Google Scholar
  21. 21.
    Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60(8):646–9.CrossRefGoogle Scholar
  22. 22.
    Kim JH, Sinn DH, Lee JH, Hyun D, Cho SK, Shin SW, Chang Y, Kim YJ, Yoon JH, Kang W, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Choi MS. Novel Albumin-Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Chemoembolization. Dig Dis Sci 2018;63(4):1062–71.CrossRefGoogle Scholar
  23. 23.
    Hiraoka A, Kumada T, Kudo M, Hirooka M, Koizumi Y, Hiasa Y, Tajiri K, Toyoda H, Tada T, Ochi H, Joko K, Shimada N, Deguchi A, Ishikawa T, Imai M, Tsuji K, Michitaka K, Real-life Practice Experts for HCCSG, Group HCC. Hepatic function during repeated TACE procedures and prognosis after introducing sorafenib in patients with unresectable hepatocellular carcinoma: Multicenter analysis. Dig Dis 2017;35(6):602–10.CrossRefGoogle Scholar
  24. 24.
    Edeline J, Blanc JF, Campillo-Gimenez B, Ma YT, King J, Faluyi O, Mathurin J, Ghazi S, Palmer DH, Meyer T. Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score. Eur J Cancer 2017;86:135–42.CrossRefGoogle Scholar
  25. 25.
    Shindoh J, Andreou A, Aloia TA, Zimmitti G, Lauwers GY, Laurent A, Nagorney DM, Belghiti J, Cherqui D, Poon RT, Kokudo N, Vauthey JN. Microvascular invasion does not predict long-term survival in hepatocellular carcinoma up to 2 cm: reappraisal of the staging system for solitary tumors. Ann Surg Oncol 2013;20(4):1223–9.CrossRefGoogle Scholar
  26. 26.
    Vauthey JN, Lauwers GY, Esnaola NF, Do KA, Belghiti J, Mirza N, Curley SA, Ellis LM, Regimbeau JM, Rashid A, Cleary KR, Nagorney DM. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002;20(6):1527–36.CrossRefGoogle Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2018

Authors and Affiliations

  • Junichi Shindoh
    • 1
    • 2
  • Yusuke Kawamura
    • 3
  • Yuta Kobayashi
    • 1
  • Yoshitaka Kiya
    • 1
  • Toshitaka Sugawara
    • 1
  • Norio Akuta
    • 3
  • Masahiro Kobayashi
    • 3
  • Yoshiyuki Suzuki
    • 3
  • Kenji Ikeda
    • 3
  • Masaji Hashimoto
    • 1
  1. 1.Hepatobiliary-pancreatic Surgery Division, Department of Gastroenterological SurgeryToranomon HospitalTokyoJapan
  2. 2.Okinaka Memorial Institute for Medical DiseaseTokyoJapan
  3. 3.Department of HepatologyToranomon HospitalTokyoJapan

Personalised recommendations